The survival analysis result suggested high-expression DOCK4 gene as a potential poor prognosis biomarker among sarcoma (SARC), stomach adenocarcinoma (STAD), and uterine corpus endometrial carcinoma (UCEC) (Figures 3(a)–3(c)), while low-expression DOCK4 gene as a potential poor prognosis biomarker among kidney renal clear cell carcinoma (KIRC) and head and neck squamous cell carcinoma (HNSC) (Figures 3(d) and 3(e)). This evidence concerns the gene DOCK4 and sarcoma.